Business Description
CelLBxHealth PLC
ISIN : GB0034330679
Total Employee Number:
119Description
CelLBxHealth PLC is engaged in the development and commercialisation of the Parsortix platform, with deployment in liquid biopsy - non-invasive cancer diagnostics. It operates in single segment of commercialisation of its Parsortix cell separation platform. It generates revenue from contracts with customers in the research-use market, with customers located across multiple geographic regions. Geographically it operates in UK, Europe, North America, and Rest of World with majority of revenue deriving from Europe and North America.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.05 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -19.31 | |||||
Beneish M-Score | -8.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23.8 | |||||
3-Year EPS without NRI Growth Rate | 13.1 | |||||
3-Year FCF Growth Rate | 28.2 | |||||
3-Year Book Growth Rate | -66 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 71.89 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 90.16 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.22 | |||||
9-Day RSI | 36.79 | |||||
14-Day RSI | 42.5 | |||||
3-1 Month Momentum % | 91.67 | |||||
6-1 Month Momentum % | 64.29 | |||||
12-1 Month Momentum % | -73.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.76 | |||||
Quick Ratio | 2.41 | |||||
Cash Ratio | 1.95 | |||||
Days Inventory | 1042.72 | |||||
Days Sales Outstanding | 231.09 | |||||
Days Payable | 806.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -63.3 | |||||
Shareholder Yield % | -35.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.58 | |||||
Operating Margin % | -1140.04 | |||||
Net Margin % | -1444.04 | |||||
EBITDA Margin % | -1000.96 | |||||
FCF Margin % | -704.07 | |||||
OCF Margin % | -685.64 | |||||
ROE % | -156.78 | |||||
ROA % | -104.28 | |||||
ROIC % | -157.08 | |||||
3-Year ROIIC % | -71.11 | |||||
ROC (Joel Greenblatt) % | -298.6 | |||||
ROCE % | -125.01 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.16 | |||||
PB Ratio | 2.59 | |||||
Price-to-Tangible-Book | 1.45 | |||||
EV-to-EBIT | -0.58 | |||||
EV-to-Forward-EBIT | -1.87 | |||||
EV-to-EBITDA | -0.81 | |||||
EV-to-Forward-EBITDA | -2.2 | |||||
EV-to-Revenue | 8.1 | |||||
EV-to-Forward-Revenue | 5.35 | |||||
EV-to-FCF | -1.21 | |||||
Price-to-GF-Value | 0.24 | |||||
Price-to-Median-PS-Value | 0.05 | |||||
Earnings Yield (Greenblatt) % | -175.31 | |||||
FCF Yield % | -57.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CelLBxHealth PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 1.351 | ||
| EPS (TTM) (£) | -0.055 | ||
| Beta | 2.1224 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.27 | ||
| Volatility % | 171.86 | ||
| 14-Day RSI | 42.5 | ||
| 14-Day ATR (£) | 0.001857 | ||
| 20-Day SMA (£) | 0.015988 | ||
| 12-1 Month Momentum % | -73.46 | ||
| 52-Week Range (£) | 0.0085 - 0.07995 | ||
| Shares Outstanding (Mil) | 1,136.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CelLBxHealth PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CelLBxHealth PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-14 | In 67 days | ||
| Second quarter earnings results for 2026 | 2026-09-14 | In 67 days | ||
| General meeting for 2025 | 2026-07-14 08:00 | In 6 days | ||
| Fourth quarter earnings conference call for 2025 | 2026-06-22 10:00 | 0.02 (-2.78%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-22 | 0.02 (-2.78%) | ||
| Annual report for 2025 | 2026-06-19 | 0.02 (-1.41%) | ||
| Analyst meeting for 2025 | 2025-11-26 14:00 | 0.01 (-4.35%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-09 10:00 | 0.06 (-14.81%) | ||
| Second quarter earnings results for 2025 | 2025-09-09 | 0.06 (-14.81%) | ||
| General meeting for 2024 | 2025-06-30 14:00 | 0.08 (+0.00%) |
Show
Entries
CelLBxHealth PLC Frequently Asked Questions
What is CelLBxHealth PLC(LSE:CLBX)'s stock price today?
The current price of LSE:CLBX is £0.01. The 52 week high of LSE:CLBX is £0.08 and 52 week low is £0.01.
When is next earnings date of CelLBxHealth PLC(LSE:CLBX)?
The next earnings date of CelLBxHealth PLC(LSE:CLBX) is 2026-09-14 Est..
Does CelLBxHealth PLC(LSE:CLBX) pay dividends? If so, how much?
CelLBxHealth PLC(LSE:CLBX) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients | 2021-07-09 | ||
| Angle PLC Announces Exercise of Options and Total Voting Rights | 2021-04-30 | ||
| Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker | 2021-02-18 | ||
| Angle PLC Announces Holding(s) in Company - (1) | 2020-07-08 | ||
| Angle PLC Announces Holding(s) in Company - (2) | 2020-07-08 | ||
| Angle PLC Announces AACR 2019 | 2019-04-11 |
Articles on CelLBxHealth PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers